JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases
Nat Rev Drug Discov 2017;16:843–62 DOI: 10.1038/nrd.2017.201
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Nat Rev Drug Discov 2017;16:843–62 DOI: 10.1038/nrd.2017.201
N Engl J Med 2017; 377:1537-50. DOI: 10.1056/NEJMoa1615975
N Engl J Med 2017;377:1525–36.
J Am Acad Dermatol 2017;76:405–17. doi: 10.1016/j.jaad.2016.11.041
Guselkumab demonstrated superiority to adalimumab and placebo in treating PsO in this Phase 3 study. Improvements in IGA and PASI scores were observed as early as Week 16 and were maintained up to Week 48. Incidence of adverse events was similar across both treatment groups.
J Am Acad Dermatol 2017;76:418–31. doi: 10.1016/j.jaad.2016.11.042
Patients treated with guselkumab showed an improved and sustained clinical response compared to both adalimumab and placebo, without compromising safety profile. The Phase 3 VOYAGE 2 trial by Reich et al focused on treatment interruption and withdrawal, as well as treatment switching from adalimumab to guselkumab.
Drug Saf. 2016 June 9; 39:755–762; DOI 10.1007/s40264-016-0431-z [Epub ahead of print]
N Engl J Med 2016;375:345–56. doi: 10.1056/NEJMoa1512711
Gordon, et al. pool the results of UNCOVER-1, UNCOVER-2, and UNCOVER-3 to show that ixekizumab increases the proportion of patients achieving an sPGA score of 0/1 or PASI 75 versus placebo. Adverse events related to ixekizumab treatment included neutropenia, candidal infections, and inflammatory bowel disease.
Arthritis Rheumatol. 2016 Mar 24. DOI 10.1002/art.39700 [Epub ahead of print]
Adv Ther. 2016 Mar 12. DOI 10.1007/s12325-016-0312-y
Annals of the Rheumatic Diseases. 2015 Sep 9. doi:10.1136/annrheumdis-2014-207201